Skip to main content
Back to News
Mecara CEO Hiromi Kawamata has been named to the EY Entrepreneurial Winning Women Asia-Pacific Class...
General
1 min read

Mecara CEO Hiromi Kawamata has been named to the EY Entrepreneurial Winning Women Asia-Pacific Class...

The AMW Read

Provides an incremental update on a specialized player in the AI-driven healthcare/diagnostics sub-segment, noting their regulatory pursuit and government grant.
NoveltySignificance
Healthcare & Bio · Player Map

Mecara CEO Hiromi Kawamata has been named to the EY Entrepreneurial Winning Women Asia-Pacific Class of 2026, recognizing her work in AI-driven digital pupillometry that measures autonomic nervous system function in just 7 seconds. The Tokyo-based startup, founded in 2019, has secured a 700 million yen government medical innovation grant and is pursuing PMDA regulatory approval for its AiLive device, which serves hospitals and corporations across Japan. Mecara plans to expand across Asia-Pacific and enter the US market within 3-5 years, transitioning from a hardware device model to a comprehensive SaaS and data analytics platform for preventive health.

#HealthTech #AI #Japan #Pupillometry #DigitalHealth #MedTech

Read Original

How This Connects

Based on Healthcare & Bio · Player Map

  1. 4d agoMedipal launches Medipal AI agent platform for specialized clinic operationsMedipal
  2. 1w agoOpenAI Launches GPT-Rosalind, a Specialized Frontier Model for Life Sciences Research and Drug DiscoveryOpenAI
  3. 1w agoIntroducing GPT-Rosalind for life sciences researchOpenAI
  4. 0mo agoMecara CEO Hiromi Kawamata has been named to the EY Entrepreneurial Winning Women Asia-Pacific Class... · THIS ARTICLE

Related News

Discover AI Startups

Explore 2,000+ AI companies with VC-grade analysis, funding data, and investment insights.

Explore Dashboard